Retatrutide (LY3437943) is a novel peptide compound classified as a GLP-1/GIP/glucagon triple receptor agonist. It is among the most researched next-generation metabolic peptides, combining three distinct receptor targets into a single molecule for multi-pathway signaling analysis.

Triple Receptor Mechanism

Retatrutide activates three receptor classes simultaneously: the GLP-1 receptor (incretin and satiety signaling), the GIP receptor (glucose-dependent insulinotropic polypeptide, involved in insulin secretion and lipid metabolism), and the glucagon receptor (energy expenditure, hepatic glucose production, and lipolysis). This tri-receptor profile is studied for potentially differentiated downstream signaling compared to single or dual agonist compounds.

Research Applications

Energy expenditure studies: The glucagon receptor component makes retatrutide of particular interest in research examining energy expenditure pathways distinct from GLP-1-only compounds.

Lipolysis pathway research: Glucagon receptor activation is associated with adipocyte lipolysis signaling — researchers study whether tri-agonism produces additive or synergistic effects on lipid mobilization.

Comparative receptor pharmacology: Retatrutide is frequently used alongside semaglutide and tirzepatide in comparative receptor binding and downstream signaling studies.

Procurement Considerations

Retatrutide’s structural complexity and similarity to other GLP-1 analogs requires rigorous identity verification. Mass spectrometry confirmation of molecular weight is essential — HPLC purity testing alone cannot differentiate retatrutide from related triple agonist sequences. Researchers should require lot-specific COA documentation including MS data before procurement.

Research use only. Not for human or animal use. OligoPoly Labs supplies retatrutide with verified HPLC and mass spectrometry documentation.